TransThera Bioscience Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
121
- Stock Symbol
-
02617
- Share Price
-
$3.82
- (As of Thursday Closing)
TransThera Bioscience General Information
Description
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its Core Product Tinengotinib is a unique multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
Contact Information
Website
www.transthera.comCorporate Office
- Biotech and Pharmaceutical Valley
- 3rd floor, Building, Accelerator Phase 2
- Nanjing, Jiangsu 210032
- China
Corporate Office
- Biotech and Pharmaceutical Valley
- 3rd floor, Building, Accelerator Phase 2
- Nanjing, Jiangsu 210032
- China
TransThera Bioscience Timeline
TransThera Bioscience Stock Performance
As of 10-Jul-2025, TransThera Bioscience’s stock price is $3.82. Its current market cap is $1.52B with 397M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.82 | $3.93 | $2.57 - $4.46 | $1.52B | 397M | 1.55M | -$0.10 |
TransThera Bioscience Financials Summary
As of 31-Dec-2024, TransThera Bioscience has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167 | 18 |
| EBITDA | (37,648) | (37,648) | (49,175) | |
| Net Income | (38,271) | (38,271) | (48,537) | |
| Total Assets | 86,246 | 86,246 | 125,143 | |
| Total Debt | 599 | 599 | 678 |
TransThera Bioscience Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TransThera Bioscience Comparisons
Industry
Financing
Details
TransThera Bioscience Competitors (3)
One of TransThera Bioscience’s 3 competitors is Ascentage Pharma, a Formerly VC-backed company based in Suzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ascentage Pharma | Formerly VC-backed | Suzhou, China | ||||
| Genfleet | Venture Capital-Backed | Shanghai, China | ||||
| I-Mab Biopharma | Formerly VC-backed | Shanghai, China |
TransThera Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TransThera Bioscience Patents
TransThera Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4582418-A1 | Crystalline form of quinoline derivative inhibitor, preparation method therefor and use thereof | Pending | 29-Aug-2023 | ||
| AU-2023371859-A1 | Nlrp3 inflammasome inhibitor and use thereof | Pending | 04-Nov-2022 | ||
| AU-2023370466-A1 | Crystal form of imidazopyrazine derivative, preparation method therefor and use thereof | Pending | 26-Oct-2022 | ||
| AU-2023335534-A1 | Crystalline form of quinoline derivative inhibitor, preparation method therefor and use thereof | Pending | 30-Aug-2022 | ||
| EP-4461729-A1 | Antigen binding protein targeting msln and use thereof | Pending | 07-Jan-2022 | A61K31/502 |
TransThera Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TransThera Bioscience FAQs
-
When was TransThera Bioscience founded?
TransThera Bioscience was founded in 2014.
-
Where is TransThera Bioscience headquartered?
TransThera Bioscience is headquartered in Nanjing, China.
-
What is the size of TransThera Bioscience?
TransThera Bioscience has 121 total employees.
-
What industry is TransThera Bioscience in?
TransThera Bioscience’s primary industry is Drug Discovery.
-
Is TransThera Bioscience a private or public company?
TransThera Bioscience is a Public company.
-
What is TransThera Bioscience’s stock symbol?
The ticker symbol for TransThera Bioscience is 02617.
-
What is the current stock price of TransThera Bioscience?
As of 10-Jul-2025 the stock price of TransThera Bioscience is $3.82.
-
What is the current market cap of TransThera Bioscience?
The current market capitalization of TransThera Bioscience is $1.52B.
-
Who are TransThera Bioscience’s competitors?
Ascentage Pharma, Genfleet, and I-Mab Biopharma are competitors of TransThera Bioscience.
-
What is TransThera Bioscience’s annual earnings per share (EPS)?
TransThera Bioscience’s EPS for 12 months was -$0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
